Metabolic modes of action of the statins in the hyperlipoproteinemias
- PMID: 9862169
- DOI: 10.1016/s0021-9150(98)00198-1
Metabolic modes of action of the statins in the hyperlipoproteinemias
Abstract
Conflicting results have been published during the past few years regarding the physiologic modes of action of the hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitors, generally referred to as statins, using standard doses. Three mechanisms have been described: increased LDL catabolic rate, increased removal of LDL precursors resulting in decreased LDL production and decreased VLDL production. The physiologic effects of statins seem to depend on the underlying pathology of the disorders under therapy. More recent data using either the more potent atorvastatin or larger doses of previously available statins (e.g. simvastatin 80-160 mg/day), suggest that both the potency of the statins and the underlying pathopHysiology are important in determining the predominant physiologic responses of patients. To understand physiologic responses more completely, drug-dose-physiologic response curves of apo B kinetics in various groups of patients are needed. Simultaneous studies of apo B, triglycerides and cholesterol metabolism are also needed and are currently feasible.
Similar articles
-
Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates.Atherosclerosis. 2002 Sep;164(1):129-45. doi: 10.1016/s0021-9150(02)00052-7. Atherosclerosis. 2002. PMID: 12119202 Clinical Trial.
-
Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig: atorvastatin versus simvastatin.Biochem Pharmacol. 1999 Oct 1;58(7):1209-19. doi: 10.1016/s0006-2952(99)00203-8. Biochem Pharmacol. 1999. PMID: 10484079
-
[Variability of the hypolipidemic action of simvastatin and fluvastatin in patients with primary hyperlipoproteinemia].Ter Arkh. 1998;70(12):8-13. Ter Arkh. 1998. PMID: 10067240 Russian.
-
Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ("statins") in familial combined hyperlipidemia.Am J Cardiol. 1998 Feb 26;81(4A):43B-46B. doi: 10.1016/s0002-9149(98)00037-x. Am J Cardiol. 1998. PMID: 9526813 Review.
-
New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.Clin Ther. 2013 Aug;35(8):1082-98. doi: 10.1016/j.clinthera.2013.06.019. Epub 2013 Aug 8. Clin Ther. 2013. PMID: 23932550 Review.
Cited by
-
Ciprofibrate therapy in patients with hypertriglyceridemia and low high density lipoprotein (HDL)-cholesterol: greater reduction of non-HDL cholesterol in subjects with excess body weight (The CIPROAMLAT study).Cardiovasc Diabetol. 2004 Jul 23;3:8. doi: 10.1186/1475-2840-3-8. Cardiovasc Diabetol. 2004. PMID: 15272932 Free PMC article.
-
Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers.Br J Clin Pharmacol. 2002 Nov;54(5):472-7. doi: 10.1046/j.1365-2125.2002.01688.x. Br J Clin Pharmacol. 2002. PMID: 12445025 Free PMC article. Clinical Trial.
-
Postoperative Cardiac Surgery Outcomes in a Statin-Native Population.Anesth Essays Res. 2018 Jan-Mar;12(1):223-228. doi: 10.4103/aer.AER_229_17. Anesth Essays Res. 2018. PMID: 29628586 Free PMC article.
-
Simvastatin induces apoptosis of fibroblast-like synoviocytes.Open Rheumatol J. 2009 Sep 7;3:35-40. doi: 10.2174/1874312900903010035. Open Rheumatol J. 2009. PMID: 19771181 Free PMC article.
-
The comorbidity burden of diabetes and stroke: a retrospective study in Beijing, China.BMC Public Health. 2025 Feb 10;25(1):546. doi: 10.1186/s12889-025-21705-8. BMC Public Health. 2025. PMID: 39930417 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous